"
Team:UCL London
From 2010.igem.org
Jameswbrown (Talk | contribs) |
|||
| Line 1: | Line 1: | ||
| - | |||
| Line 11: | Line 10: | ||
Synthetic biology is now in a position to overcome many, hitherto, | Synthetic biology is now in a position to overcome many, hitherto, | ||
| - | cumbersome and resource consuming | + | cumbersome and resource consuming manufacturing tasks. Society has |
| - | now accepted the advent of | + | now accepted the advent of such entities as recombinant insulin , |
monoclonal antibodies etc as essential for the future well being of | monoclonal antibodies etc as essential for the future well being of | ||
human life. We can now use the bio engineered tools available to us | human life. We can now use the bio engineered tools available to us | ||
| Line 19: | Line 18: | ||
To this end, this project addresses the hypothesis that we can use | To this end, this project addresses the hypothesis that we can use | ||
| - | auto-induction as means of control of production recombinant products | + | auto-induction as a means of control of production of recombinant products |
| - | at pre-destined time in large production vessels thus alleviating the | + | at a pre-destined time in large production vessels thus alleviating the |
need for extra resources. To illustrate this we are using E.coli as | need for extra resources. To illustrate this we are using E.coli as | ||
our main vehicle with the prospect of removing the need for IPTG | our main vehicle with the prospect of removing the need for IPTG | ||
| - | induction as mechanism for the production a vast array of | + | induction as a mechanism for the production of a vast array of |
biopharmaceuticals. We expect this technology to be equally | biopharmaceuticals. We expect this technology to be equally | ||
| - | applicable to other systems such as yeast and mammalian cells. | + | applicable to other systems such as yeast and mammalian cells.'' |
|[[Image:UCL_London_team.png|right|frame|Your team picture]] | |[[Image:UCL_London_team.png|right|frame|Your team picture]] | ||
|- | |- | ||
Revision as of 16:27, 17 July 2010
File:UCL London logo.png 200px | |
|
Artificial biomanufacturing intelligence system ABIS Synthetic biology is now in a position to overcome many, hitherto, cumbersome and resource consuming manufacturing tasks. Society has now accepted the advent of such entities as recombinant insulin , monoclonal antibodies etc as essential for the future well being of human life. We can now use the bio engineered tools available to us to create systems which make manufacturing health or environmentally associated products simpler and more economical. To this end, this project addresses the hypothesis that we can use auto-induction as a means of control of production of recombinant products at a pre-destined time in large production vessels thus alleviating the need for extra resources. To illustrate this we are using E.coli as our main vehicle with the prospect of removing the need for IPTG induction as a mechanism for the production of a vast array of biopharmaceuticals. We expect this technology to be equally applicable to other systems such as yeast and mammalian cells. | File:UCL London team.png Your team picture |
| Team Example |
| Home | Team | Official Team Profile | Project | Parts Submitted to the Registry | Modeling | Notebook | Safety |
|---|
